Type 2 diabetes: The role of basal insulin therapy

Journal of Family Practice

Volumn 53, Issue 3, 2004, Pages 215-222

  LeRoith, Derek ^a,g   Levetan, Claresa S ^b,c   Hirsch, Irl B ^d,e   Riddle, Matthew C ^f  

^a Drexel Univ College of Medicine ^*

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL;

AUTONOMIC NEUROPATHY; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DIET THERAPY; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN TREATMENT; KIDNEY DISEASE; LEG AMPUTATION; MASS SCREENING; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK FACTOR; STROKE; UNITED STATES;

CHILD; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 1542358041     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003; 26:917-932.
2. National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates an diabetes in the United States, 2000. Bethesda, Md: U.S. Department of Health and Human Services, National Institutes of Health, 2002. National Institute of Diabetes and Digestive and Kidney Diseases, 2002.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-234.
4. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003; 289:2254-2264.
5. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997; 157:1802-1817.
6. Stratton IM, Adler AJ, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000; 321:405-412.
7. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno-2 randomised study. Lancet. 1999; 353:617-622.
8. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348:383-393.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998; 317:703-713.
10. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care. 2003; 26(suppl 1):S1-S156.
11. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
12. National Institutes of Health, National Heart Lung and Blood Institute. JNC 7 Express: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, Md: US Dept of Health and Human Services; May 2003. NIH publication 03-5233. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/express. Accessed November 14, 2003.
13. American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management: 2000 update. Endocr Pract. 2000; 8(suppl 1):40-82.
14. Woolf SH, Davidson MB, Greenfield S, et al. Controlling blood glucose levels in patients with type 2 diabetes mellitus: an evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association. J Fam Pract. 2000; 49:453-460.
15. National Committee for Quality Assurance. The State of Health Care Quality. 2003. Washington, DC: NCQA; 2003: 1-34.
16. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Venkat Narayan KMV. A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med. 2002; 136:565-574.
17. Suwattee P, Lynch JC, Pendergrass ML. Quality of care for diabetic patients in a large urban public hospital. Diabetes Care. 2003; 26:563-568.
18. Fleming BB, Greenfield S, Engelgau MM, Pogach LM, Clauser SB, Parrott MA. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care. 2001; 24:1815-1820.
19. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care. 2004; 27:S11-S14.
20. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med. 2003; 138:212-214.
21. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26:3160-3167.
22. Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults: United States, 1999-2000. Morb Mortal Wkly Rep. 2003; 52:833-837.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853.
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-865.
25. Feld S. AACE diabetes guidelines. Endocr Pract. 2002; 8(suppl 1):41-65.
26. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002; 25:330-336.
27. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002; 18:S42-S49.
28. Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone. 2001; 4:50-64.
29. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999; 131:182-188.
30. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Meora TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000; 23:639-643.
31. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000; 23:1130-1136.
32. Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003; 26:3080-3086.
33. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care. 1982; 5:353-363.
34. Malmberg K, and the DIGAMI (Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction) Study Group. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. Br Med J. 1997; 314:1512-1515.
35. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997; 20:292-298.
36. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2003; 138:952-959.
37. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49:2142-2148.
38. Full U.S. Prescribing Information for Lantus. Available at: http://www.lantus.com/professional/home.jsp. Accessed March 5, 2003.
39. DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes: clinical applications. JAMA. 2003; 289:2265-2269.
40. Rosenstock J, Schwartz SL, Clark CM, Jr., Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001; 24:631-636.
41. Raut M, Sung JCY, Law AW. Cost of treating hypoglycemia among patients with diabetes [abstract]. Diabetes Care. 2003; 26(suppl 2):A1152.